DFDina Fathalla

Dina Fathalla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dina Fathalla has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Abigail T. Armstrong

    Department of Industrial and Physical Pharmacy, Purdue University, 575 West Stadium Avenue, West Lafayette, IN 47907, USA

    1 shared publication
  • Acar

    Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland

    1 shared publication
  • Angharad Morgan

    Systems Immunity University Research Institute, Cardiff University, Cardiff, UK

    1 shared publication
  • Anneke I. Den Hollander

    Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands

    1 shared publication
  • Anthony T. Moore

    UCL Institute of Ophthalmology, University College London, London, EC1V 9EL, UK

    1 shared publication
  • B Paul Morgan

    Systems Immunity University Research Institute, Cardiff University, Cardiff, UK

    1 shared publication

Latest Publications

  • Size optimization of carfilzomib nanocrystals for systemic delivery to solid tumors

    by Hytham H. Gadalla, Seongsoo Lee, Hyungjun Kim, Abigail T. Armstrong, Dina Fathalla, Fawzia Habib, Hyunyoung Jeong, Wooin Lee, Yoon Yeo


  • Open Access

    Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration

    by Valentina Cipriani, Laura Lorés-Motta, Fan He, Dina Fathalla, Viranga Tilakaratna, Selina McHarg, Nadhim Bayatti, İlHan E. Acar, Carel B. Hoyng, Sascha Fauser, et al.

    Age-related macular degeneration (AMD) is a leading cause of blindness. Genetic variants at the chromosome 1q31.3 encompassing the complement factor H (CFH, FH) and CFH related genes (CFHR1-5) are major determinants of AMD susceptibility, but their molecular consequences remain unclear. Here we demonstrate that FHR-4 plays a prominent role in AMD pathogenesis. We show that systemic FHR-4 levels are elevated in AMD (P-value = 7.1 × 10−6), whereas no difference is seen for FH. Furthermore, FHR-4 accumulates in the choriocapillaris, Bruch’s membrane and drusen, and can compete with FH/FHL-1 for C3b binding, preventing FI-mediated C3b cleavage. Critically, the protective allele of the strongest AMD-associated CFH locus variant rs10922109 has the highest association with reduced FHR-4 levels (P-value = 2.2 × 10−56), independently of the AMD-protective CFHR1–3 deletion, and even in those individuals that carry the high-risk allele of rs1061170 (Y402H). Our findings identify FHR-4 as a key molecular player contributing to complement dysregulation in AMD.


  • Cerebrospinal fluid complement system biomarkers in demyelinating disease

    by Wioleta Milena Zelek, Dina Fathalla, Angharad Morgan, Samuel Touchard, Samantha Loveless, Emma Tallantyre, Neil P Robertson, B Paul Morgan

    Background: Multiple sclerosis (MS) can be difficult to differentiate from other demyelinating diseases, notably neuromyelitis optica spectrum disorder (NMOSD). We previously showed that NMOSD is distinguished from MS by plasma complement biomarkers. Objective: Here, we measure cerebrospinal fluid (CSF) complement proteins in MS, NMOSD and clinically isolated syndrome (CIS), a neurological episode that may presage MS, to test whether these distinguish NMOSD from MS and CIS. Materials and methods: CSF (53 MS, 17 CIS, 11 NMOSD, 35 controls) was obtained; complement proteins (C4, C3, C5, C9, C1, C1q, Factor B (FB)), regulators (Factor I (FI), Factor H (FH), FH-Related Proteins 1, 2 and 5 (FHR125), C1 Inhibitor (C1INH), Properdin) and activation products (terminal complement complex (TCC), iC3b) were quantified by ELISA and results expressed relative to CSF total protein (μg/mg). Results: Compared to control CSF, (1) levels of C4, C1INH and Properdin were elevated in MS; (2) TCC, iC3b, FI and FHR125 were increased in CIS; and (3) all complement biomarkers except TCC, FHR125, Properdin and C5 were higher in NMOSD CSF. A statistical model comprising six analytes (C3, C9, FB, C1q, FI, Properdin) plus age/gender optimally differentiated MS from NMOSD.